AI Drug Discovery Trial Reveals Promise and Challenges of Using the Tech - PYMNTS.com
AI's potential in drug discovery is highlighted by Recursion Pharmaceuticals' Phase 2 SYCAMORE trial for REC-994, targeting cerebral cavernous malformation, which met safety endpoints but showed mixed efficacy. Despite AI's ability to analyze vast datasets, challenges include data scarcity for rare conditions and predicting drug efficacy accurately. Experts suggest developing more complex AI models and combining AI with traditional techniques to advance drug discovery.
Highlighted Terms
Related News
AI's potential in drug discovery is highlighted by Recursion Pharmaceuticals' Phase 2 SYCAMORE trial for REC-994, targeting cerebral cavernous malformation, which met safety endpoints but showed mixed efficacy. Despite AI's ability to analyze vast datasets, challenges include data scarcity for rare conditions and predicting drug efficacy accurately. Experts suggest developing more complex AI models and combining AI with traditional techniques to advance drug discovery.